What's New in Pigmentary Disorders

Dermatol Clin. 2019 Apr;37(2):175-181. doi: 10.1016/j.det.2018.12.008. Epub 2019 Feb 16.

Abstract

Pigmentary disorders are common and can be very distressing to patients. There is a need for better, standardized therapies. The authors review the most recent data for topical, systemic, light, and laser treatments for vitiligo, melasma, and postinflammatory hyperpigmentation. There is a paucity of large-scale, well-designed, randomized, controlled trials for these treatments. Treatment options are often drawn from smaller trials and case series. The treatments described in this article are promising candidates for larger follow-up studies.

Keywords: Management; Melasma; Pigmentary disorders; Postinflammatory hyperpigmentation; Vitiligo.

Publication types

  • Review

MeSH terms

  • Antifibrinolytic Agents / therapeutic use
  • Bimatoprost / therapeutic use
  • Dermatologic Agents / therapeutic use*
  • Humans
  • Hydroquinones / therapeutic use
  • Inflammation
  • Janus Kinase Inhibitors / therapeutic use*
  • Keratinocytes / transplantation
  • Lasers, Solid-State / therapeutic use
  • Low-Level Light Therapy
  • Melanocytes / transplantation
  • Melanosis
  • Pigmentation Disorders / therapy*
  • Skin Lightening Preparations / therapeutic use
  • Sunscreening Agents / therapeutic use
  • Tranexamic Acid / therapeutic use
  • Vitiligo / therapy
  • alpha-MSH / analogs & derivatives
  • alpha-MSH / therapeutic use

Substances

  • Antifibrinolytic Agents
  • Dermatologic Agents
  • Hydroquinones
  • Janus Kinase Inhibitors
  • Skin Lightening Preparations
  • Sunscreening Agents
  • alpha-MSH
  • Tranexamic Acid
  • afamelanotide
  • Bimatoprost
  • hydroquinone